MedTrace Logo

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

NCT04179890 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 462

Last updated 2023-05-25

Study results available
· View outcomes & findings →

Summary

Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated with an EGFR-TKI

Conditions

  • Non-squamous, Non-Small Cell Lung Cancer

Interventions

DRUG

Afatinib (Gi(l)otrif®)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

DRUG

Erlotinib (Tarceva®)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

DRUG

Gefitinib (IRESSA®)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

DRUG

Osimertinib (Tagrisso®)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

DRUG

Afatinib (Gi(l)otrif®)

As first line therapy.

DRUG

Osimertinib (Tagrisso®)

In the case the T790M resistance mutation was developed (second line therapy).

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-17
Primary Completion
2021-07-22
Completion
2021-07-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04179890 on ClinicalTrials.gov